A FTSE 250 growth share I’d buy to target a multibagger return

I’ve been looking for a FTSE 250 growth stock to add to my 2024 Stocks and Shares ISA. I think I might have found it.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Buying FTSE 250 shares can sometimes give us a white-knuckle ride. But then, the mid-cap index has trounced the FTSE 100 in long-term returns.

We’re looking at a long-term average return from the smaller index of around 11% per year, against closer to 7%.

FTSE 250 stocks have been falling back again in the past few years, but they’re starting to make gains once more.

Should you invest £1,000 in Puretech Health Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Puretech Health Plc made the list?

See the 6 stocks

FTSE 250 growth

There are some big dividends from the FTSE 250, but today I have my eye on a pure growth stock.

It’s biotech research firm PureTech Health (LSE: PRTC). And its share price over the past five years has been… how pale are those knuckles again?

Created with Highcharts 11.4.3PureTech Health Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Explosive growth?

Let’s look at an obvious negative. PureTech is not producing regular profit, and forecasts don’t show any in the next couple of years.

But, the company has just completed a share buyback to the tune of $100m. Isn’t it a bit strange for a company that’s not in profit to be returning cash? Well, yes.

But the $14bn sale of the PureTech-founded Karuna Therapeutics to Bristol Myers Squibb made a big difference to the cash pile.

And at the end of the last full year on 31 March, the company reported cash, equivalents, and short-term investments of $573m. The board reckons there’s enough to keep it going for the next few years.

Clinical research

The future is all about the possibilities for PureTech’s research. It specialises in medicines related to the brain, gut, and immune system. And it has a number of candidates making their way through the regulatory systems in the EU and the US.

As well as it’s own research, PureTech has fingers in a lot of other pies, through its ‘Founded Entities’ approach… like that Karuna success.

It has stakes in a range of firms, working in the neuropsychiatric, oncology, immunology, and other fields.

The way forward

It’s all down to hopes for PureTech’s research pipeline, and those of its Founded Entities. But for me, I see the approach here as more attractive than most in this business.

Speaking of the firm’s internal research targets, CEO Bharatt Chowrira spoke of the options open to advance them.

He spoke of “progressing them in Founded Entities or through partnerships” as one way. And when the firm launches a new firm like this, they’ve recently been oversubscribed.

Oh, and the CEO also pointed out that “We take great pride in our track record of clinical success, which is six times the industry average“.

A buy?

Buying PureTech Health shares now would be very speculative. We just don’t have the usual measures to value it. There’s no useful price-to-earnings (P/E) ratio, no dividend yield, etc.

But, analysts do expect strong sales from PureTech in the next couple of years.

It’s tricky weighing this against the other stocks on my wanted list. But if I buy, it’ll only be small amount, as there’s a chance of losing it. But if it comes good, I might hope for a multibagger here.

Of course, there are plenty of other passive income opportunities to explore. And these may be even more lucrative:

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£10,000 invested in Greatland Gold shares 1 year ago is now worth

Greatland Gold shares have caught my eye in recent months, partially because of the trade volume, but also the recent…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Think the FTSE 100 has no good growth stocks? Think again…

The S&P 500 has a more impressive array of growth stocks than the FTSE 100. But investors who ignore the…

Read more »

Mature couple at the beach
Investing Articles

Here’s how a £100k SIPP could turn into a £1m+ SIPP in 30 years

Christopher Ruane sees a SIPP as an ideal vehicle for long-term investment. Here he explains how an investor could aim…

Read more »

Investing Articles

£2K in savings? Here’s how that could be used to start investing today

With a spare couple of thousands pounds, a stock market beginner could start investing. Our writer shares some thoughts to…

Read more »

Man smiling and working on laptop
Investing Articles

2 hot REITS to consider for a long-term second income!

A lump sum or regular investment in these real estate investment trusts (REITs) could help supercharge an investor's second income.

Read more »

Investing Articles

My favourite FTSE 100 stock has just doubled my money! What do I do?

Harvey Jones has reaped outsized rewards from private equity specialist 3i Group, the top-performing FTSE 100 stock over five years.…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 rookie ISA mistakes to avoid

Seemingly small choices can have big impact on the long-term valuation of a Stocks and Shares ISA. This writer identifies…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

FTSE shares: 3 reasons I’m buying this February

Christopher Ruane reckons that now is as good a time as any for him to buy specific FTSE 100 shares.…

Read more »